Moderna News - October 21, 2026

🟢 Moderna is trading 4.03% up today amid melanoma-vaccine optimism

Moderna is trading 4.03% higher at $251.84 on October 21 as investors focus on positive Phase 3 results for its personalized melanoma vaccine with Merck. - The...

Moderna and Merck Prepare FDA Filing for Personalized Melanoma Vaccine

Moderna and Merck are preparing to seek FDA approval for intismeran autogene, a personalized mRNA vaccine for patients with high-risk melanoma that has been...